Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis

References

• Anonymous. Cancer Facts and Figures. American Cancer Society, GA, USA (2008).
   Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl. J. Med.351(18), 1860–1873 (2004).
   PubMed Web of Science ®Google Scholar
• Saad AA, Sharma M, Higa GM. Treatment of multiple myeloma in the targeted therapy era. Ann. Pharmacother.43(2), 329–338 (2009).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med.346(8), 564–569 (2002).
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood113(22), 5412–5417 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood113(22), 5418–5422 (2009).
   PubMed Web of Science ®Google Scholar
• Stewart AK, Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev. Mol. Diagn.7(4), 453–459 (2007).
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer2(3), 175–187 (2002).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood104(3), 607–618 (2004).
   PubMed Web of Science ®Google Scholar
• Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature425(6960), 841–846 (2003).
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity25(6), 977–988 (2006).
   PubMed Web of Science ®Google Scholar
• Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell131(2), 324–336 (2007).
   PubMed Web of Science ®Google Scholar
• Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature460(7252), 259–263 (2009).
   PubMed Web of Science ®Google Scholar
• Wu JY, Purton LE, Rodda SJ et al. Osteoblastic regulation of B lymphopoiesis is mediated by Gs{α}-dependent signaling pathways. Proc. Natl Acad. Sci. USA105(44), 16976–16981 (2008).
   PubMed Web of Science ®Google Scholar
• Mariani S, Coscia M, Even J et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br. J. Haematol.113(4), 1051–1059 (2001).
   PubMed Web of Science ®Google Scholar
• Massaia M, Bianchi A, Attisano C et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood78(7), 1770–1780 (1991).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature441(7090), 235–238 (2006).
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Barbuto S, Matthews P et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17–1 cells) enriched in the bone marrow of patients with myeloma. Blood112(7), 2878–2885 (2008).
   PubMed Web of Science ®Google Scholar
• Prabhala RPD, Fulciniti M, Nanjappa P et al. TH17 pathway promotes tumor cell growth and suppresses immune function in myeloma: potential for therapeutic application. HematologistII, 831 (2009).
   Google Scholar
• Dhodapkar MV, Geller MD, Chang DH et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med.197(12), 1667–1676 (2003).
   PubMed Web of Science ®Google Scholar
• Kukreja A, Hutchinson A, Dhodapkar K et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J. Exp. Med.203(8), 1859–1865 (2006).
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood100(1), 230–237 (2002).
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7–1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and IL-10. Blood98(10), 2992–2998 (2001).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med.2(10), 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• Xie J, Wang Y, Freeman ME, Barlogie B 3rd, Yi Q. β2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit In vitro generation of functional dendritic cells. Blood101(10), 4005–4012 (2003).
   PubMed Web of Science ®Google Scholar
• Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47-thrombospondin-1 interactions in myeloma induced fusion of human dendritic cells: implications for bone disease. Blood114(16), 3413–3421 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Wang S et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood114(17), 3625–3628 (2009).
   PubMed Web of Science ®Google Scholar
• Scavelli C, Nico B, Cirulli T et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene27(5), 663–674 (2008).
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Davies FE et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood98(2), 428–435 (2001).
   PubMed Web of Science ®Google Scholar
• de Bont ES, Guikema JE, Scherpen F et al. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin’s lymphoma. Cancer Res.61(20), 7654–7659 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang H, Vakil V, Braunstein M et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood105(8), 3286–3294 (2005).
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood105(4), 1383–1395 (2005).
   PubMed Web of Science ®Google Scholar
• Jakob C, Sterz J, Zavrski I et al. Angiogenesis in multiple myeloma. Eur. J. Cancer42(11), 1581–1590 (2006).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene25(31), 4257–4266 (2006).
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Asosingh K, Allegaert V et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia18(5), 976–982 (2004).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Mesa RA, Fonseca R et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin. Cancer Res.8(7), 2210–2216 (2002).
   PubMed Web of Science ®Google Scholar
• Ria R, Todoerti K, Berardi S et al. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin. Cancer Res.15(17), 5369–5378 (2009).
   PubMed Web of Science ®Google Scholar
• Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer91(7), 1219–1230 (2001).
   PubMed Web of Science ®Google Scholar
• Corre J, Mahtouk K, Attal M et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia21(5), 1079–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Arnulf B, Lecourt S, Soulier J et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia21(1), 158–163 (2007).
   PubMed Web of Science ®Google Scholar
• Zdzisinska B, Walter-Croneck A, Kandefer-Szerszen M. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients. Leuk. Res.32(11), 1763–1769 (2008).
   PubMed Web of Science ®Google Scholar
• Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood108(13), 3992–3996 (2006).
   PubMed Web of Science ®Google Scholar
• Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract. Res. Clin. Haematol.20(4), 613–624 (2007).
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood87(11), 4762–4769 (1996).
   PubMed Web of Science ®Google Scholar
• Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood110(4), 1098–1104 (2007).
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med.349(26), 2483–2494 (2003).
   PubMed Web of Science ®Google Scholar
• Qiang YW, Chen Y, Stephens O et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood112(1), 196–207 (2008).
   PubMed Web of Science ®Google Scholar
• Oshima T, Abe M, Asano J et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood106(9), 3160–3165 (2005).
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest.88(1), 62–66 (1991).
   PubMed Web of Science ®Google Scholar
• Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J. Histochem. Cytochem.57(3), 239–247 (2009).
   PubMed Web of Science ®Google Scholar
• Yang Y, Yaccoby S, Liu W et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood100(2), 610–617 (2002).
   PubMed Web of Science ®Google Scholar
• Kelly T, Miao HQ, Yang Y et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res.63(24), 8749–8756 (2003).
   PubMed Web of Science ®Google Scholar
• Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod. Pathol.14(10), 1052–1058 (2001).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br. J. Haematol.99(2), 368–371 (1997).
   PubMed Web of Science ®Google Scholar
• Seidel C, Sundan A, Hjorth M et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood95(2), 388–392 (2000).
   PubMed Web of Science ®Google Scholar
• Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood99(4), 1405–1410 (2002).
   PubMed Web of Science ®Google Scholar
• Mahtouk K, Cremer FW, Reme T et al. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene25(54), 7180–7191 (2006).
   PubMed Web of Science ®Google Scholar
• Jakobsson L, Kreuger J, Holmborn K et al. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell10(5), 625–634 (2006).
   PubMed Web of Science ®Google Scholar
• Filla MS, Dam P, Rapraeger AC. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J. Cell. Physiol.174(3), 310–321 (1998).
   PubMed Web of Science ®Google Scholar
• Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol.38(12), 2018–2039 (2006).
   PubMed Web of Science ®Google Scholar
• Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood112(1), 159–168 (2008).
   PubMed Web of Science ®Google Scholar
• Vincent T, Jourdan M, Sy MS, Klein B, Mechti N. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J. Biol. Chem.276(18), 14728–14736 (2001).
   PubMed Web of Science ®Google Scholar
• van Driel M, Gunthert U, Stauder R, Joling P, Lokhorst HM, Bloem AC. CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. Leukemia12(11), 1821–1828 (1998).
   PubMed Web of Science ®Google Scholar
• Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood93(12), 4144–4148 (1999).
   PubMed Web of Science ®Google Scholar
• Jain A, McKnight DA, Fisher LW et al. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin. Cancer Res.15(16), 5199–5207 (2009).
   PubMed Web of Science ®Google Scholar
• Woitge HW, Pecherstorfer M, Horn E et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br. J. Cancer84(3), 344–351 (2001).
   PubMed Web of Science ®Google Scholar
• Kawano M, Hirano T, Matsuda T et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature332(6159), 83–85 (1988).
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood85(4), 863–872 (1995).
   PubMed Web of Science ®Google Scholar
• Braunstein EM, White SJ. Non-Hodgkin lymphoma of bone. Radiology135(1), 59–63 (1980).
   PubMed Web of Science ®Google Scholar
• Tai YT, Podar K, Kraeft SK et al. Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. Exp. Hematol.30(3), 212–220 (2002).
   PubMed Web of Science ®Google Scholar
• Wen XY, Stewart AK, Sooknanan RR et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int. J. Oncol.15(1), 173–178 (1999).
   PubMed Web of Science ®Google Scholar
• Reimold AM, Iwakoshi NN, Manis J et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature412(6844), 300–307 (2001).
   PubMed Web of Science ®Google Scholar
• Chauhan D, Li G, Auclair D et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood101(9), 3606–3614 (2003).
   PubMed Web of Science ®Google Scholar
• Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol.4(4), 321–329 (2003).
   PubMed Web of Science ®Google Scholar
• Carrasco DR, Sukhdeo K, Protopopova M et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell11(4), 349–360 (2007).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene20(42), 5991–6000 (2001).
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle3(10), 1259–1262 (2004).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Hayashi T et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol. Cancer Ther.1(7), 539–544 (2002).
   PubMed Web of Science ®Google Scholar
• Moreaux J, Cremer FW, Reme T et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood106(3), 1021–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Breitkreutz I et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res.66(13), 6675–6682 (2006).
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood100(6), 2195–2202 (2002).
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-α (MIP-1 α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood101(9), 3568–3573 (2003).
   PubMed Web of Science ®Google Scholar
• Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood96(2), 671–675 (2000).
   PubMed Web of Science ®Google Scholar
• Bloomston M, Zervos EE, Rosemurgy AS 2nd. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann. Surg. Oncol.9(7), 668–674 (2002).
   PubMed Web of Science ®Google Scholar
• Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol. Biomarkers Prev.16(7), 1474–1478 (2007).
   PubMed Web of Science ®Google Scholar
• Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R. Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk. Lymphoma44(3), 543–545 (2003).
   PubMed Web of Science ®Google Scholar
• Standal T, Borset M, Lenhoff S et al. Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood100(12), 3925–3929 (2002).
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Jacobson J, Sawyer J et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood101(10), 3849–3856 (2003).
   PubMed Web of Science ®Google Scholar
• Qiang YW, Yao L, Tosato G, Rudikoff S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood103(1), 301–308 (2004).
   PubMed Web of Science ®Google Scholar
• Ehrlich LA, Chung HY, Ghobrial I et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood106(4), 1407–1414 (2005).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Yamauchi M, Sugimoto T et al. The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. Biochem. Biophys. Res. Commun.299(4), 532–538 (2002).
   PubMed Web of Science ®Google Scholar
• Yano S, Macleod RJ, Chattopadhyay N et al. Calcium-sensing receptor activation stimulates parathyroid hormone-related protein secretion in prostate cancer cells: role of epidermal growth factor receptor transactivation. Bone35(3), 664–672 (2004).
   PubMed Web of Science ®Google Scholar
• Jackson C, Nguyen M, Arkell J, Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis – targetting gelatinase A activation. Inflamm. Res.50(4), 183–186 (2001).
   PubMed Web of Science ®Google Scholar
• Lindberg RL, De Groot CJ, Montagne L et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain124(Pt 9), 1743–1753 (2001).
   PubMed Web of Science ®Google Scholar
• Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer99(2), 157–166 (2002).
   PubMed Web of Science ®Google Scholar
• Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1–MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene27(23), 3274–3281 (2008).
   PubMed Web of Science ®Google Scholar
• Barille S, Akhoundi C, Collette M et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood90(4), 1649–1655 (1997).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood93(9), 3064–3073 (1999).
   PubMed Web of Science ®Google Scholar
• Wahlgren J, Maisi P, Sorsa T et al. Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions. J. Pathol.194(2), 217–224 (2001).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Ribatti D et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica88(2), 176–185 (2003).
   PubMed Web of Science ®Google Scholar
• Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (Matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J. Immunol.163(10), 5723–5728 (1999).
   PubMed Web of Science ®Google Scholar
• Werb Z, Mainardi CL, Vater CA, Harris ED Jr. Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N. Engl. J. Med.296(18), 1017–1023 (1977).
   PubMed Web of Science ®Google Scholar
• Devy L, Noel A, Baramova E et al. Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells. Biochem. Biophys. Res. Commun.238(3), 842–846 (1997).
   PubMed Web of Science ®Google Scholar
• Asosingh K, Menu E, Van Valckenborgh E et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin. Exp. Metastasis19(7), 583–591 (2002).
   PubMed Web of Science ®Google Scholar
• Hjertner O, Qvigstad G, Hjorth-Hansen H et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br. J. Haematol.109(4), 815–822 (2000).
   PubMed Web of Science ®Google Scholar
• Thabard W, Barille S, Collette M et al. Myeloma cells release soluble interleukin-6Ra in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. Clin. Cancer Res.5(10), 2693–2697 (1999).
   PubMed Web of Science ®Google Scholar
• Hargreaves PG, Wang F, Antcliff J et al. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br. J. Haematol.101(4), 694–702 (1998).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol.87(3), 503–508 (1994).
   PubMed Web of Science ®Google Scholar
• Van Valckenborgh E, De Raeve H, Devy L et al. Murine 5T multiple myeloma cells induce angiogenesis In vitro and in vivo. Br. J. Cancer86(5), 796–802 (2002).
   PubMed Web of Science ®Google Scholar
• Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells15(3), 180–189 (1997).
   PubMed Web of Science ®Google Scholar
• Van Valckenborgh E, Bakkus M, Munaut C et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int. J. Cancer101(6), 512–518 (2002).
   PubMed Web of Science ®Google Scholar
• Sato T, Foged NT, Delaisse JM. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J. Bone Miner. Res.13(1), 59–66 (1998).
   PubMed Web of Science ®Google Scholar
• Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL. Initiation of osteoclast bone resorption by interstitial collagenase. J. Biol. Chem.272(35), 22053–22058 (1997).
   PubMed Web of Science ®Google Scholar
• Everts V, Delaisse JM, Korper W, Beertsen W. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J. Bone Miner. Res.13(9), 1420–1430 (1998).
   PubMed Web of Science ®Google Scholar
• Derenne S, Amiot M, Barille S et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res.14(12), 2048–2056 (1999).
   PubMed Web of Science ®Google Scholar
• Hajitou A, Sounni NE, Devy L et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res.61(8), 3450–3457 (2001).
   PubMed Web of Science ®Google Scholar
• Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood100(9), 3361–3368 (2002).
   PubMed Web of Science ®Google Scholar
• Ikenaka Y, Yoshiji H, Kuriyama S et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int. J. Cancer105(3), 340–346 (2003).
   PubMed Web of Science ®Google Scholar
• Docherty AJ, Lyons A, Smith BJ et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature318(6041), 66–69 (1985).
   PubMed Web of Science ®Google Scholar
• Hayakawa T. Tissue inhibitors of metalloproteinases and their cell growth-promoting activity. Cell Struct. Funct.19(3), 109–114 (1994).
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett.298(1), 29–32 (1992).
   PubMed Web of Science ®Google Scholar
• Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol.74(2), 111–122 (1997).
   PubMed Web of Science ®Google Scholar
• Hernandez-Barrantes S, Toth M, Bernardo MM et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem.275(16), 12080–12089 (2000).
   PubMed Web of Science ®Google Scholar
• Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res.58(11), 2310–2315 (1998).
   PubMed Web of Science ®Google Scholar
• Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer79(9–10), 1347–1355 (1999).
   PubMed Web of Science ®Google Scholar
• Guedez L, Stetler-Stevenson WG, Wolff L et al.In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest.102(11), 2002–2010 (1998).
   PubMed Web of Science ®Google Scholar
• Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res.59(24), 6267–6275 (1999).
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA, Shrivastava V et al. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk. Res.34(3), 399–402 (2009).
   PubMed Web of Science ®Google Scholar
• Guedez L, Martinez A, Zhao S et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. Blood105(4), 1660–1668 (2005).
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood93(5), 1658–1667 (1999).
   PubMed Web of Science ®Google Scholar
• Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene19(38), 4319–4327 (2000).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Presta M et al. α(v)β(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp. Hematol.29(8), 993–1003 (2001).
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med.359(22), 2313–2323 (2008).
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group: criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol.121, 749–757 (2003).
   Google Scholar
• Harousseau JL and Moreau P. Autologous hematopoietic stem cell transplantion for multiple myeloma. N. Engl. J. Med.360(25), 2645–2654 (2009).
   PubMed Web of Science ®Google Scholar